News
MENS
2.010
-3.37%
-0.070
Jyong Biotech FY25 net loss widens 55% to US$4.67 million
PUBT · 17h ago
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Barchart · 20h ago
Weekly Report: what happened at MENS last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at MENS last week (0427-0501)?
Weekly Report · 05/04 09:05
Jyong Biotech Delays Annual 20-F (Yearly Report)
TipRanks · 04/29 18:19
Jyong Biotech delays annual Form 20-F filing, cites audit completion needs
PUBT · 04/29 17:12
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
PR Newswire · 04/29 00:00
Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
Benzinga · 04/28 12:37
Weekly Report: what happened at MENS last week (0420-0424)?
Weekly Report · 04/27 09:05
Weekly Report: what happened at MENS last week (0413-0417)?
Weekly Report · 04/20 09:05
Jyong Biotech files Form 3; CFO Zhang Wei reports no beneficial ownership
PUBT · 04/14 15:46
Weekly Report: what happened at MENS last week (0406-0410)?
Weekly Report · 04/13 09:05
Jyong Biotech files Form 3 showing CEO Fu-Feng Kuo as 10% owner
Reuters · 04/08 14:12
Weekly Report: what happened at MENS last week (0330-0403)?
Weekly Report · 04/06 09:05
Jyong Biotech files Form 3 as director Hsu Ming Tsan reports beneficial ownership
Reuters · 04/01 19:45
Jyong Biotech files Form 3 as director Hsu Feng-Lin reports beneficial ownership
Reuters · 04/01 19:34
Jyong Biotech director Hsu Feng-Lin files initial beneficial ownership statement
Reuters · 04/01 19:21
Jyong Biotech files Form 3 initial beneficial ownership statement for director Fan Hung-Shu
Reuters · 04/01 19:10
Jyong Biotech director Chi Pang-Chieh files initial beneficial ownership statement
Reuters · 04/01 18:57
Weekly Report: what happened at MENS last week (0323-0327)?
Weekly Report · 03/30 09:05
More
Webull provides a variety of real-time MENS stock news. You can receive the latest news about Jyong Biotech Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About MENS
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.